KPTI News and Press, Karyopharm Therapeutics Inc. From 07/03/19

-- XPOVIO is the First and Only Nuclear Export Inhibitor Approved by the FDA -- -- XPOVIO is the First and Only Prescription Medicine Approved by the FDA for the Treatment of Patients with Multiple Myeloma whose Disease is Refractory to Proteasome Inhibitors, Immunomodulatory Age...

Nasdaq has suspended trading in Karyopharm Therapeutics ( KPTI +36% ) pending the release of news, in this case pertaining to the FDA nod for multiple myeloma med XPOVIO (selinexor). The agency's formal action date is Saturday, July 6, meaning that an announcement should be made today cons...

Gainers:  OMNOVA Solutions (NYSE: OMN ) +55% . SELLAS Life Sciences Group (NASDAQ: SLS ) +46% . Karyopharm Therapeutics (NASDAQ: KPTI ) +36% . One Stop Systems (NASDAQ: OSS ) +26% . NIO (NYSE: NIO ) +15% . Corvus Pharmaceuticals (NASDAQ: CRVS ) +15% . Melinta Therapeutics (NASDA...

Noteworthy events during the week of June 30 - July 6 for healthcare investors. More news on: Jazz Pharmaceuticals plc, Celyad SA, Array BioPharma Inc., Healthcare stocks news, , Read more ...

-- Single-Agent Oral Selinexor Induces a 28.3% Overall Response Rate,  Including a 10.2% Complete Response Rate -- -- Amongst Patients with a Complete or Partial Response, Median Duration of Response was 9.2 Months -- NEWTON, Mass., June 19, 2019 (GLOBE NEWSWIRE) -- Karyopharm...

Karyopharm Therapeutics (NASDAQ: KPTI )  gains 4.0%  in premarket trading after presenting new and updated data from its Phase 1b/2 STOMP study evaluating selinexor and dexamethasone in combination with standard approved multiple myeloma therapies in patients with previously treate...

− Once Weekly Oral Selinexor in Combination with Kyprolis® and Low Dose Dexamethasone Demonstrates 78% ORR in Patients with Heavily Pretreated, Kyprolis-Naïve Multiple Myeloma – − Once Weekly Oral Selinexor in Combination with Darzalex® and Low Dose...

Noteworthy events during the week of June 9 - 15 for healthcare investors. More news on: Merck & Co., Inc., Xeris Pharmaceuticals, Inc., Mallinckrodt plc, Healthcare stocks news, , Read more ...

The following slide deck was published by Karyopharm Therapeutics Inc. in conjunction with this Read more ...

-- Oral Presentation Highlighting Updated Data from the Phase 1b/2 STOMP Study Arm Evaluating Selinexor and Dexamethasone in Combination with Darzalex® in Patients with Relapsed or Refractory Multiple Myeloma -- -- Two Posters Highlighting Updated Data from the STOMP Arms Evaluat...